These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33738725)

  • 1. The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults.
    Alonso-Cotoner C; Abril-Gil M; Albert-Bayo M; Mall JG; Expósito E; González-Castro AM; Lobo B; Santos J
    Adv Ther; 2021 May; 38(5):2054-2076. PubMed ID: 33738725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mucoprotectants in the management of gastrointestinal disorders.
    Eutamene H; Beaufrand C; Harkat C; Theodorou V
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):83-90. PubMed ID: 28946778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome.
    Valentin N; Camilleri M; Carlson P; Harrington SC; Eckert D; O'Neill J; Burton D; Chen J; Shaw AL; Acosta A
    Physiol Rep; 2017 Mar; 5(5):. PubMed ID: 28275113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
    Iakovenko EP; Agafonova NA; Pokhal'skaia OIu; Kolganova AV; Nazarbekova RS; Ivanov AN; Davletshina IV; Popova EV; Prianishnikova AS; Ovchinnikova NI; Iakovenko AV; Aldiiarova MA; D'iachkoava AV; Gioeva IZ
    Klin Med (Mosk); 2008; 86(10):47-52. PubMed ID: 19069460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome.
    Sayuk GS
    Gastroenterol Clin North Am; 2021 Sep; 50(3):611-637. PubMed ID: 34304791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D.
    Singh P; Silvester J; Chen X; Xu H; Sawhney V; Rangan V; Iturrino J; Nee J; Duerksen DR; Lembo A
    United European Gastroenterol J; 2019 Jun; 7(5):709-715. PubMed ID: 31210949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea.
    Piovezani Ramos G; Camilleri M
    Dig Dis Sci; 2023 May; 68(5):1677-1690. PubMed ID: 36376576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Bertrand J; Ghouzali I; Guérin C; Bôle-Feysot C; Gouteux M; Déchelotte P; Ducrotté P; Coëffier M
    JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1170-1176. PubMed ID: 25972430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial.
    Ko SJ; Ryu B; Kim J; Hong BG; Yeo I; Lee BJ; Lee JM; Park JW
    Trials; 2011 Oct; 12():219. PubMed ID: 21978382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Momordica charantia polysaccharides alleviate diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and barrier via NF-κB pathway.
    Ji S; Zhang Q
    Allergol Immunopathol (Madr); 2022; 50(3):62-70. PubMed ID: 35527657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
    Brenner DM; Sayuk GS
    Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
    Barbara G
    Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier.
    Prospero L; Riezzo G; Linsalata M; Orlando A; D'Attoma B; Russo F
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.
    Dunlop SP; Hebden J; Campbell E; Naesdal J; Olbe L; Perkins AC; Spiller RC
    Am J Gastroenterol; 2006 Jun; 101(6):1288-94. PubMed ID: 16771951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome.
    Yang M; Zhang L; Hong G; Li Y; Li G; Qian W; Xiong H; Bai T; Song J; Hou X
    J Gastroenterol Hepatol; 2020 May; 35(5):795-805. PubMed ID: 31674052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Barrier and Gut Microbiota in Patients with Overlapping Irritable Bowel Syndrome and Functional Dyspepsia.
    Kovaleva A; Poluektova E; Maslennikov R; Karchevskaya A; Shifrin O; Kiryukhin A; Tertychnyy A; Kovalev L; Kovaleva M; Lobanova O; Kudryavtseva A; Krasnov G; Ivashkin V
    Dig Dis Sci; 2023 Nov; 68(11):4166-4174. PubMed ID: 37752368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea.
    Lopetuso L; Graziani C; Guarino A; Lamborghini A; Masi S; Stanghellini V
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(4):873-883. PubMed ID: 28272692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways.
    Xie Y; Zhan X; Tu J; Xu K; Sun X; Liu C; Ke C; Cao G; Zhou Z; Liu Y
    J Ethnopharmacol; 2021 May; 272():113925. PubMed ID: 33592255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea.
    Vazquez-Roque MI; Camilleri M; Smyrk T; Murray JA; O'Neill J; Carlson P; Lamsam J; Eckert D; Janzow D; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2012 Dec; 303(11):G1262-9. PubMed ID: 23042942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.